Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Benzimidazoles"" wg kryterium: Temat


Tytuł :
Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.
Autorzy :
Makhlouf NA; Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Abdelmalek MO; Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Ibrahim ME; Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Abu-Faddan NH; Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.
Kheila AE; Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Mahmoud AA; Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Pokaż więcej
Źródło :
Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2021 Feb 13; Vol. 10 (1), pp. 7-13.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents/*therapeutic use
Benzimidazoles/*therapeutic use
Fluorenes/*therapeutic use
Hematologic Diseases/*complications
Hepacivirus/*genetics
Hepatitis C, Chronic/*drug therapy
Liver/*pathology
Sofosbuvir/*therapeutic use
Adolescent ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Drug Therapy, Combination ; Elasticity Imaging Techniques ; Female ; Fluorenes/administration & dosage ; Fluorenes/adverse effects ; Hepacivirus/drug effects ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/pathology ; Hepatitis C, Chronic/virology ; Humans ; Liver/drug effects ; Male ; Sofosbuvir/administration & dosage ; Sofosbuvir/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists.
Autorzy :
Song Z; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023 China.
Wang X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhang Y; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Gu W; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Shen A; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Ding C; Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Li H; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023 China.
Xiao R; Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Geng M; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Xie Z; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhang A; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023 China.; University of Chinese Academy of Sciences, Beijing 100049, China.; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Feb 11; Vol. 64 (3), pp. 1649-1669. Date of Electronic Publication: 2021 Jan 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*chemical synthesis
Antineoplastic Agents/*pharmacology
Benzimidazoles/*chemical synthesis
Benzimidazoles/*pharmacology
Membrane Proteins/*agonists
Animals ; Antineoplastic Agents/pharmacokinetics ; Benzimidazoles/pharmacokinetics ; Humans ; Mice ; Mice, Inbred BALB C ; Models, Molecular ; Solubility ; Structure-Activity Relationship ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Antimicrobial evaluation of myricetin derivatives containing benzimidazole skeleton against plant pathogens.
Autorzy :
Chen M; State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China.
Tang X; State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China.
Liu T; State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China.
Peng F; State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China.
Zhou Q; State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China.
Luo H; State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China.
He M; State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China.
Xue W; State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China. Electronic address: .
Pokaż więcej
Źródło :
Fitoterapia [Fitoterapia] 2021 Mar; Vol. 149, pp. 104804. Date of Electronic Publication: 2020 Dec 11.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-Bacterial Agents/*pharmacology
Benzimidazoles/*pharmacology
Flavonoids/*pharmacology
Plant Diseases/*microbiology
Anti-Bacterial Agents/chemistry ; Benzimidazoles/chemistry ; Copper/pharmacology ; Flavonoids/chemistry ; Molecular Structure ; Oryza/microbiology ; Ralstonia solanacearum/drug effects ; Structure-Activity Relationship ; Sulfhydryl Compounds/pharmacology ; Thiadiazoles/pharmacology ; Xanthomonas/drug effects
SCR Organism :
Xanthomonas oryzae
Czasopismo naukowe
Tytuł :
Silver microspheres aggregation-induced Raman enhanced scattering used for rapid detection of carbendazim in Chinese tea.
Autorzy :
He J; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Li H; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Zhang L; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Zhi X; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Li X; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Wang X; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Feng Z; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Shen G; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China. Electronic address: .
Ding X; Institute for Personalized Medicine, State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China. Electronic address: .
Pokaż więcej
Źródło :
Food chemistry [Food Chem] 2021 Mar 01; Vol. 339, pp. 128085. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :
Journal Article
MeSH Terms :
Microspheres*
Spectrum Analysis, Raman*
Benzimidazoles/*analysis
Carbamates/*analysis
Food Contamination/*analysis
Pesticide Residues/*analysis
Silver/*chemistry
Tea/*chemistry
Benzimidazoles/chemistry ; Carbamates/chemistry ; Color ; Humans ; Limit of Detection ; Pesticide Residues/chemistry ; Time Factors
Czasopismo naukowe
Tytuł :
In-silico driven design and development of spirobenzimidazo-quinazolines as potential DNA gyrase inhibitors.
Autorzy :
Korrapati SB; Medicinal Chemistry and Pharmacology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500 007, India.
Yedla P; Division of Applied Biology, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500 085, India.
Pillai GG; Discovery Chemistry, Nyro Research India, Kochi, Kerala, 682 021, India.
Mohammad F; Surfactants Research Chair, Department of Chemistry, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia. Electronic address: .
Ch VRR; Department of Chemistry, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad, 500 085, India.
Bhamidipati P; School of Chemistry, University of Hyderabad, 500 046, India.
Amanchy R; Division of Applied Biology, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500 085, India. Electronic address: .
Syed R; Department of Chemistry, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad, 500 085, India. Electronic address: .
Kamal A; Medicinal Chemistry and Pharmacology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500 007, India; School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi, 110 062, India. Electronic address: .
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Feb; Vol. 134, pp. 111132. Date of Electronic Publication: 2020 Dec 24.
Typ publikacji :
Journal Article
MeSH Terms :
Computer-Aided Design*
Drug Design*
Anti-Bacterial Agents/*pharmacology
Bacteria/*drug effects
Benzimidazoles/*pharmacology
DNA Gyrase/*metabolism
Quinazolines/*pharmacology
Topoisomerase II Inhibitors/*pharmacology
Anti-Bacterial Agents/chemical synthesis ; Bacteria/growth & development ; Benzimidazoles/chemical synthesis ; Binding Sites ; Biofilms/drug effects ; Biofilms/growth & development ; DNA Gyrase/chemistry ; Green Chemistry Technology ; Microbial Sensitivity Tests ; Molecular Docking Simulation ; Molecular Structure ; Protein Binding ; Quantitative Structure-Activity Relationship ; Quinazolines/chemical synthesis ; Topoisomerase II Inhibitors/chemical synthesis
Czasopismo naukowe
Tytuł :
Evaluation of the Efficacy and Safety of Azilsartan in Adult Patients with Essential Hypertension: A Randomized, Phase-III Clinical Study in India.
Autorzy :
Sinha S; Hetero Group of Pharmaceutical Companies, Clinical Development and Medical Affairs, Hetero Corporate, Hyderabad, Telangana.
Chary S; Hetero Group of Pharmaceutical Companies, Clinical Development and Medical Affairs, Hetero Corporate, Hyderabad, Telangana.
Reddy Bandi M; Hetero Group of Pharmaceutical Companies, Clinical Development and Medical Affairs, Hetero Corporate, Hyderabad, Telangana.
Thakur P; Hetero Group of Pharmaceutical Companies, Clinical Development and Medical Affairs, Hetero Corporate, Hyderabad, Telangana.
Talluri L; Hetero Group of Pharmaceutical Companies, Clinical Development and Medical Affairs, Hetero Corporate, Hyderabad, Telangana.
Reddy VK; Cardiology Department, Mediciti Hospital, Hyderabad, Telangana.
Agarwal M; Medical Director, Medilink Hospital & Research Centre, Ahmedabad, Gujarat.
Naik K S; Rajiv Gandhi Institute of Medical Sciences, Srikakulam, Andhra Pradesh.
Azilsartan Study In Indian Adult Patients Of Essential Hypertension Investigators Azilehi Group; AZILEHI Group includes: Kajal Ganguly, NRS Medical College and Hospital, Kolkata, West Bengal, Karthik Vikrambhai Patel, Kanoria Hospital & Research Centre, Gandhi Nagar, Gujarat; Mahesh Pal Khatri, S.P. Medical college, Bikaner, Rajasthan; Manoj Kumar, Nirmal Hospital, Jhansi, Uttar Pradesh; Priyadarshi, GSVM Medical College, Kanpur, Uttar Pradesh; Srinivas Reddy, King George Hospital, Vishakapatnam, Andhra Pradesh.
Pokaż więcej
Źródło :
The Journal of the Association of Physicians of India [J Assoc Physicians India] 2021 Feb; Vol. 69 (2), pp. 35-39.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Benzimidazoles*/adverse effects
Essential Hypertension*/drug therapy
Hypertension*/drug therapy
Adult ; Antihypertensive Agents/adverse effects ; Blood Pressure ; Double-Blind Method ; Female ; Humans ; India ; Male ; Oxadiazoles ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Autorzy :
Nyffenegger N; Vifor (International) Ltd., Rechenstrasse 37, 9014 St. Gallen, Switzerland.
Flace A; Vifor (International) Ltd., Rechenstrasse 37, 9014 St. Gallen, Switzerland.
Doucerain C; Vifor (International) Ltd., Rechenstrasse 37, 9014 St. Gallen, Switzerland.
Dürrenberger F; Vifor (International) Ltd., Rechenstrasse 37, 9014 St. Gallen, Switzerland.
Manolova V; Vifor (International) Ltd., Rechenstrasse 37, 9014 St. Gallen, Switzerland.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jan 16; Vol. 22 (2). Date of Electronic Publication: 2021 Jan 16.
Typ publikacji :
Journal Article
MeSH Terms :
Benzimidazoles/*pharmacology
Erythropoiesis/*drug effects
Oxazoles/*pharmacology
Pyridines/*pharmacology
beta-Thalassemia/*drug therapy
Administration, Oral ; Animals ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzimidazoles/therapeutic use ; Cation Transport Proteins/antagonists & inhibitors ; Cells, Cultured ; Deferasirox/administration & dosage ; Deferasirox/pharmacology ; Deferasirox/therapeutic use ; Drug Combinations ; Drug Interactions ; Female ; Iron/blood ; Iron Chelating Agents/administration & dosage ; Iron Chelating Agents/pharmacology ; Iron Chelating Agents/therapeutic use ; Male ; Mice ; Mice, Inbred C57BL ; Oxazoles/administration & dosage ; Oxazoles/adverse effects ; Oxazoles/therapeutic use ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyridines/therapeutic use ; Transferrin/metabolism
Czasopismo naukowe
Tytuł :
A highly sensitive detection of carbendazim pesticide in food based on the upconversion-MnO 2 luminescent resonance energy transfer biosensor.
Autorzy :
Ouyang Q; School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China. Electronic address: .
Wang L; School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.
Ahmad W; School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.
Rong Y; School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.
Li H; School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.
Hu Y; School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.
Chen Q; School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China. Electronic address: .
Pokaż więcej
Źródło :
Food chemistry [Food Chem] 2021 Jul 01; Vol. 349, pp. 129157. Date of Electronic Publication: 2021 Jan 26.
Typ publikacji :
Journal Article
MeSH Terms :
Limit of Detection*
Benzimidazoles/*analysis
Biosensing Techniques/*methods
Carbamates/*analysis
Fluorescence Resonance Energy Transfer/*methods
Food Analysis/*methods
Food Contamination/*analysis
Aptamers, Nucleotide/chemistry ; Benzimidazoles/chemistry ; Carbamates/chemistry ; Manganese Compounds/chemistry ; Nanoparticles/chemistry ; Oxides/chemistry
Czasopismo naukowe
Tytuł :
Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential.
Autorzy :
Verma R; Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, India.
Kaushik D; Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, India.
Pokaż więcej
Źródło :
Drug delivery [Drug Deliv] 2020 Dec; Vol. 27 (1), pp. 756-771.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Angiotensin II Type 1 Receptor Blockers/*administration & dosage
Benzimidazoles/*administration & dosage
Blood Pressure/*drug effects
Drug Delivery Systems/*methods
Tetrazoles/*administration & dosage
Angiotensin II Type 1 Receptor Blockers/chemistry ; Angiotensin II Type 1 Receptor Blockers/pharmacology ; Animals ; Benzimidazoles/chemistry ; Benzimidazoles/pharmacology ; Biological Availability ; Dose-Response Relationship, Drug ; Drug Carriers/chemistry ; Drug Liberation ; Drug Stability ; Emulsions ; Excipients/chemistry ; Food-Drug Interactions ; Male ; Rats, Wistar ; Solubility ; Tetrazoles/chemistry ; Tetrazoles/pharmacology
Czasopismo naukowe
Tytuł :
Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer's disease.
Autorzy :
Mo J; School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Chen T; Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, People's Republic of China.
Yang H; School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Guo Y; School of pharmacy, Yantai University, Yantai, People's Republic of China.
Li Q; School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Qiao Y; School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Lin H; School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Feng F; Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, People's Republic of China.; Jiangsu Food and Pharmaceutical Science College, Huaian, People's Republic of China.
Liu W; School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Chen Y; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Liu Z; Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, People's Republic of China.
Sun H; School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.; Jiangsu Food and Pharmaceutical Science College, Huaian, People's Republic of China.
Pokaż więcej
Źródło :
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2020 Dec; Vol. 35 (1), pp. 330-343.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Alzheimer Disease/*drug therapy
Antioxidants/*pharmacology
Benzimidazoles/*pharmacology
Cholinesterase Inhibitors/*pharmacology
Acetylcholinesterase/metabolism ; Alzheimer Disease/metabolism ; Amyloid beta-Peptides/antagonists & inhibitors ; Amyloid beta-Peptides/metabolism ; Animals ; Antioxidants/chemical synthesis ; Antioxidants/chemistry ; Benzimidazoles/chemical synthesis ; Benzimidazoles/chemistry ; Butyrylcholinesterase/metabolism ; Cell Death/drug effects ; Cell Survival/drug effects ; Cholinesterase Inhibitors/chemical synthesis ; Cholinesterase Inhibitors/chemistry ; Dose-Response Relationship, Drug ; Electrophorus ; Hep G2 Cells ; Horses ; Humans ; Mice ; Mice, Inbred ICR ; Models, Molecular ; Molecular Structure ; PC12 Cells ; Peptide Fragments/antagonists & inhibitors ; Peptide Fragments/metabolism ; Protein Aggregates/drug effects ; Rats ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Alkylated benzimidazoles: Design, synthesis, docking, DFT analysis, ADMET property, molecular dynamics and activity against HIV and YFV.
Autorzy :
Srivastava R; Bioorganic Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad, 211002, India.
Gupta SK; Bioorganic Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad, 211002, India.
Naaz F; Bioorganic Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad, 211002, India.
Sen Gupta PS; Department of Chemical Sciences, Indian Institute of Science Education and Research Berhampur, Odisha 760010, India.
Yadav M; Bioorganic Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad, 211002, India.
Singh VK; Bioorganic Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad, 211002, India.
Singh A; Bioorganic Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad, 211002, India.
Rana MK; Department of Chemical Sciences, Indian Institute of Science Education and Research Berhampur, Odisha 760010, India.
Gupta SK; National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India.
Schols D; Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Singh RK; Bioorganic Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad, 211002, India. Electronic address: .
Pokaż więcej
Źródło :
Computational biology and chemistry [Comput Biol Chem] 2020 Dec; Vol. 89, pp. 107400. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Journal Article
MeSH Terms :
Benzimidazoles/*pharmacology
HIV/*drug effects
Reverse Transcriptase Inhibitors/*pharmacology
Yellow fever virus/*drug effects
Animals ; Benzimidazoles/chemical synthesis ; Benzimidazoles/pharmacokinetics ; Catalytic Domain ; Chlorocebus aethiops ; Density Functional Theory ; HIV/enzymology ; HIV Reverse Transcriptase/chemistry ; HIV Reverse Transcriptase/metabolism ; Microbial Sensitivity Tests ; Models, Chemical ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Molecular Structure ; Reverse Transcriptase Inhibitors/chemical synthesis ; Reverse Transcriptase Inhibitors/pharmacokinetics ; Structure-Activity Relationship ; Vero Cells ; Yellow fever virus/enzymology
Czasopismo naukowe
Tytuł :
Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Autorzy :
Imyanitov EN; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology , St.-Petersburg, 197758, Russia.; Department of Clinical Genetics, St.-Petersburg Pediatric Medical University , St.-Petersburg, 194100, Russia.; Department of Oncology, I.I. Mechnikov North-Western Medical University , St.-Petersburg, 191015, Russia.; Department of Oncology, I.P. Pavlov St.-Petersburg State Medical University , St.-Petersburg, 197022, Russia.; Institute of Medical Primatology , Sochi, 354376, Russia.
Levchenko EV; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology , St.-Petersburg, 197758, Russia.; Department of Oncology, I.I. Mechnikov North-Western Medical University , St.-Petersburg, 191015, Russia.
Kuligina ES; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology , St.-Petersburg, 197758, Russia.
Orlov SV; Department of Oncology, I.P. Pavlov St.-Petersburg State Medical University , St.-Petersburg, 197022, Russia.; Institute of Medical Primatology , Sochi, 354376, Russia.
Pokaż więcej
Źródło :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Nov; Vol. 21 (16), pp. 1943-1953. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Benzimidazoles/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Administration, Oral ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Cell Proliferation/drug effects ; Child ; Clinical Trials as Topic ; Drug Administration Schedule ; Female ; Humans ; Lung Neoplasms/mortality ; MAP Kinase Kinase Kinase 1/antagonists & inhibitors ; MAP Kinase Kinase Kinase 2/antagonists & inhibitors ; Progression-Free Survival
Czasopismo naukowe
Tytuł :
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Autorzy :
Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. .
Palmisiano N; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Mantzaris I; Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Mims A; Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
DiNardo C; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Silverman LR; Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Wang ES; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Fiedler W; Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Baldus C; Division of Hematology and Oncology, Charité University Hospital Berlin, Berlin, Germany.
Schwind S; Division of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany.
Pardee T; Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC, USA.
Perl AE; Division of Hematology-Oncology, Perelman School of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
Cai C; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Kaulfuss S; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Lagkadinou E; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Rentzsch C; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wagner M; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wilkinson G; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wu B; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Jeffers M; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Genvresse I; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Krämer A; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2903-2913. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Targeted Therapy*
Mutation*
Aniline Compounds/*therapeutic use
Antineoplastic Agents/*therapeutic use
Benzimidazoles/*therapeutic use
Enzyme Inhibitors/*therapeutic use
Isocitrate Dehydrogenase/*antagonists & inhibitors
Isocitrate Dehydrogenase/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Adult ; Aged ; Aniline Compounds/administration & dosage ; Aniline Compounds/adverse effects ; Aniline Compounds/pharmacokinetics ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzimidazoles/pharmacokinetics ; Bone Marrow/pathology ; DNA Mutational Analysis ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/pharmacokinetics ; Female ; Humans ; Isocitrate Dehydrogenase/metabolism ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Prognosis ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer.
Autorzy :
Bae HJ; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kang SK; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kwon WS; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jeong I; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Park S; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Biostatistics and Computing, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim TS; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim KH; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim H; Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jeong HC; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Chung HC; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Rha SY; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło :
Biochemical pharmacology [Biochem Pharmacol] 2021 Jan; Vol. 183, pp. 114320. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Aminopyridines/*pharmacology
Benzimidazoles/*pharmacology
DNA Methylation/*drug effects
Drug Resistance, Neoplasm/*drug effects
Genes, p16/*drug effects
Stomach Neoplasms/*metabolism
Aminopyridines/therapeutic use ; Animals ; Benzimidazoles/therapeutic use ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell Survival/physiology ; DNA Methylation/physiology ; Dose-Response Relationship, Drug ; Drug Resistance, Neoplasm/physiology ; Female ; Genes, p16/physiology ; Humans ; Mice ; Mice, Nude ; Predictive Value of Tests ; Stomach Neoplasms/drug therapy
Czasopismo naukowe
Tytuł :
Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Autorzy :
Dale DC; Department of Medicine, University of Washington, Seattle, WA.
Firkin F; Department of Medicine and.; University of Washington, Severe Chronic Neutropenia International Registry, Seattle, WA; and.
Bolyard AA; University of Washington, Severe Chronic Neutropenia International Registry, Seattle, WA; and.
Kelley M; Department of Medicine, University of Washington, Seattle, WA.
Makaryan V; Department of Medicine, University of Washington, Seattle, WA.
Gorelick KJ; X4 Pharmaceuticals, Inc, Cambridge, MA.
Ebrahim T; X4 Pharmaceuticals, Inc, Cambridge, MA.
Garg V; X4 Pharmaceuticals, Inc, Cambridge, MA.
Tang W; X4 Pharmaceuticals, Inc, Cambridge, MA.
Jiang H; X4 Pharmaceuticals, Inc, Cambridge, MA.
Skerlj R; X4 Pharmaceuticals, Inc, Cambridge, MA.
Beaussant Cohen S; X4 Pharmaceuticals, Inc, Cambridge, MA.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Dec 24; Vol. 136 (26), pp. 2994-3003.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Aminoquinolines/*administration & dosage
Benzimidazoles/*administration & dosage
Butylamines/*administration & dosage
Primary Immunodeficiency Diseases/*drug therapy
Receptors, CXCR4/*antagonists & inhibitors
Warts/*drug therapy
Administration, Oral ; Adolescent ; Adult ; Aminoquinolines/adverse effects ; Benzimidazoles/adverse effects ; Butylamines/adverse effects ; Female ; Humans ; Leukocyte Count ; Male ; Middle Aged ; Neutrophils ; Primary Immunodeficiency Diseases/blood ; Primary Immunodeficiency Diseases/genetics ; Prospective Studies ; Receptors, CXCR4/genetics ; Warts/blood ; Warts/genetics
SCR Disease Name :
WHIM syndrome
Czasopismo naukowe
Tytuł :
Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Autorzy :
Zhong C; Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kayamori K; Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
Koide S; Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shinoda D; Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Oshima M; Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Nakajima-Takagi Y; Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Nagai Y; Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
Mimura N; Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan.
Sakaida E; Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
Yamazaki S; Laboratory of Stem Cell Therapy, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Iwano S; Laboratory for Cell Function Dynamics, Center for Brain Science, RIKEN, Saitama, Japan.
Miyawaki A; Laboratory for Cell Function Dynamics, Center for Brain Science, RIKEN, Saitama, Japan.
Ito R; Humanized Model Laboratory, Central Institute for Experimental Animals, Kanagawa, Japan.
Tohyama K; Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan.
Yamaguchi K; Division of Clinical Genome Research, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Furukawa Y; Division of Clinical Genome Research, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Lennox W; PTC Therapeutics, South Plainfield, NJ, USA.
Sheedy J; PTC Therapeutics, South Plainfield, NJ, USA.
Weetall M; PTC Therapeutics, South Plainfield, NJ, USA.
Iwama A; Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Dec; Vol. 111 (12), pp. 4336-4347. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :
Journal Article
MeSH Terms :
Benzimidazoles/*pharmacology
Myelodysplastic Syndromes/*drug therapy
Pyrazines/*pharmacology
Tubulin Modulators/*pharmacology
Animals ; Antimetabolites, Antineoplastic/pharmacology ; Apoptosis/drug effects ; Apoptosis/genetics ; Benzimidazoles/therapeutic use ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Decitabine/pharmacology ; G2 Phase/drug effects ; HL-60 Cells ; Heterografts ; Humans ; Mice ; Myelodysplastic Syndromes/genetics ; Paclitaxel/pharmacology ; Pyrazines/therapeutic use ; Sequence Analysis, RNA/methods ; Tubulin/drug effects ; Tubulin Modulators/therapeutic use ; Vincristine/pharmacology
Czasopismo naukowe
Tytuł :
[European approvals: Glasdegib for Acute myeloid leukemia].
Autorzy :
Barrière S; CHU de Clermont-Ferrand, service thérapie cellulaire et hématologie clinique, 1, rue Lucie-Aubrac, 63100 Clermont-Ferrand, France. Electronic address: .
Gastaud L; Centre Lacassagne, département d'oncologie médicale, 33, avenue Valombrose, 06189 Nice cedex 2, France.
Pokaż więcej
Transliterated Title :
AMMs au niveau européen : glasdegib dans la leucémie aiguë myéloïde.
Źródło :
Bulletin du cancer [Bull Cancer] 2020 Dec; Vol. 107 (12), pp. 1206-1207. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Letter; News
MeSH Terms :
Drug Approval*
Antineoplastic Agents/*therapeutic use
Benzimidazoles/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Phenylurea Compounds/*therapeutic use
Antineoplastic Agents/adverse effects ; Azacitidine/therapeutic use ; Benzimidazoles/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Europe ; Gemtuzumab/therapeutic use ; Hedgehog Proteins/antagonists & inhibitors ; Humans ; Leukemia, Myeloid, Acute/mortality ; Phenylurea Compounds/adverse effects ; Randomized Controlled Trials as Topic ; Sulfonamides/therapeutic use
Periodyk
Tytuł :
Post-ischemic administration of dopamine D2 receptor agonist reduces cell death by activating mitochondrial pathway following ischemic stroke.
Autorzy :
Kaushik P; Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.
Ali M; Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.
Tabassum H; Division of Basic Medical Sciences, Indian Council of Medical Research, Ministry of Health and Family Welfare, Government of India, V. Ramalingaswamy Bhawan, New Delhi 110029, India.
Parvez S; Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Nov 15; Vol. 261, pp. 118349. Date of Electronic Publication: 2020 Aug 24.
Typ publikacji :
Journal Article
MeSH Terms :
Benzimidazoles/*pharmacology
Brain Ischemia/*drug therapy
Neuroprotective Agents/*pharmacology
Stroke/*drug therapy
Animals ; Behavior, Animal/drug effects ; Benzimidazoles/administration & dosage ; Brain Ischemia/pathology ; Dopamine Agonists/administration & dosage ; Dopamine Agonists/pharmacology ; Dose-Response Relationship, Drug ; Infarction, Middle Cerebral Artery ; Male ; Mitochondria/drug effects ; Mitochondria/pathology ; Neuroprotective Agents/administration & dosage ; Rats ; Rats, Wistar ; Reactive Oxygen Species/metabolism ; Receptors, Dopamine D2/agonists ; Receptors, Dopamine D2/metabolism ; Stroke/pathology ; Time Factors
Czasopismo naukowe
Tytuł :
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Autorzy :
Monk BJ; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ.
Grisham RN; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY.
Banerjee S; Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, London, United Kingdom.
Kalbacher E; Centre Hospitalier Régional et Universitaire de Besançon, CHRU de Besançon, Besançon, France.
Mirza MR; Nordic Society of Gynaecological Oncology and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Romero I; Servicio de Oncologıa Medica, Fundacion Instituto Valenciano de Oncologıa, Valencia, Spain.
Vuylsteke P; CHU Université catholique de Louvain Namur, Sainte-Elisabeth, Namur, Belgium.; University of Botswana, Gaborone, Botswana.
Coleman RL; MD Anderson Cancer Center, Houston, TX.
Hilpert F; Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Germany.
Oza AM; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Westermann A; Dutch Gynaecological Oncology Group, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Oehler MK; Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, South Australia 5005, Australia.
Pignata S; Istituto Nazionale Tumori Fondazione Pascale IRCCS, Naples, Italy.
Aghajanian C; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ.
Colombo N; Dipartimento Medicina e Chirurgia, Università Milano-Bicocca, Programma Ginecologia Oncologica Istituto Europeo Oncologia, IRCCS, Milan, Italy.
Drill E; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY.
Cibula D; First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
Moore KN; Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Christy-Bittel J; Pfizer, New York, NY.
Del Campo JM; Vall d'Hebron University Hospital, Barcelona, Spain.
Berger R; University Clinic for Gynaecology and Obstetrics, Medical University of Innsbruck, Innsbruck 6020, Austria.
Marth C; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Austrian AGO, Innsbruck, Austria.
Sehouli J; Center for Oncological Surgery, European Competence Center for Ovarian Cancer Campus Virchow Klinikum and Benjamin Franklin Charité Comprehensive Cancer Center , Medical University of Berlin, Berlin, Germany.
O'Malley DM; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
Churruca C; Biodonostia HRI, Osasun Ikerketa Insitutua, Insituto de Investigacion Sanitaria, San Sebastián, Gipuzkoa, Spain.
Boyd AP; Pfizer, New York, NY.
Kristensen G; Department for Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Clamp A; Department of Medical Oncology, The Christie National Health Service Foundation Trust, and University of Manchester, Manchester, United Kingdom.
Ray-Coquard I; Centre Léon Bérard, Netsarc Network, Université Claude Bernard Lyon 1, Lyon, France.
Vergote I; Belgium and Luxemburg Gynaecological Oncology Group, University Hospitals Leuven, Leuven, Belgium.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Nov 10; Vol. 38 (32), pp. 3753-3762. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Benzimidazoles/*therapeutic use
Cystadenocarcinoma, Serous/*drug therapy
Fallopian Tube Neoplasms/*drug therapy
Ovarian Neoplasms/*drug therapy
Peritoneal Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Benzimidazoles/adverse effects ; Cystadenocarcinoma, Serous/enzymology ; Cystadenocarcinoma, Serous/pathology ; Doxorubicin/analogs & derivatives ; Doxorubicin/therapeutic use ; Fallopian Tube Neoplasms/enzymology ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; MAP Kinase Kinase 1/antagonists & inhibitors ; MAP Kinase Kinase 2/antagonists & inhibitors ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local/drug therapy ; Ovarian Neoplasms/enzymology ; Ovarian Neoplasms/pathology ; Paclitaxel/therapeutic use ; Peritoneal Neoplasms/enzymology ; Peritoneal Neoplasms/pathology ; Polyethylene Glycols/therapeutic use ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Topotecan/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial.
Autorzy :
Khalili H; Array. .
Nourian A; Tehran University of Medical Sciences, Tehran, Iran.. .
Ahmadinejad Z; Tehran University of Medical Sciences, Tehran, Iran. .
Emadi Kouchak H; Tehran University of Medical Sciences, Tehran, Iran. .
Jafari S; Tehran University of Medical Sciences, Tehran, Iran. .
Dehghan Manshadi SA; Tehran University of Medical Sciences, Tehran, Iran. .
Rasolinejad M; Tehran University of Medical Sciences, Tehran, Iran. .
Kebriaeezadeh A; Tehran University of Medical Sciences, Tehran, Iran.. .
Pokaż więcej
Źródło :
Acta bio-medica : Atenei Parmensis [Acta Biomed] 2020 Nov 10; Vol. 91 (4), pp. e2020102. Date of Electronic Publication: 2020 Nov 10.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antiviral Agents/*therapeutic use
Benzimidazoles/*therapeutic use
COVID-19/*drug therapy
Fluorenes/*therapeutic use
Sofosbuvir/*therapeutic use
Aged ; Antiviral Agents/adverse effects ; Benzimidazoles/adverse effects ; Drug Combinations ; Fluorenes/adverse effects ; Humans ; Middle Aged ; Severity of Illness Index ; Sofosbuvir/adverse effects ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies